NCT00491868 - Clinical Study of R744 to Hemodialysis Patients | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

August 31, 2008

Conditions

Hemodialysis Patients

Interventions

DRUG

R744

100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks

DRUG

R744

150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks

DRUG

rHuEPO

2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks

DRUG

rHuEPO

4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks

DRUG

R744 placebo

0 μg/4week for 24 weeks

DRUG

rHuEPO placebo

0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks

Trial Locations (5)

Chugoku/Shikoku region, Chugoku/Shikoku

Chubu region, Chūbu

Kanto/Koshinetsu region, Kanto/Koshinetsu

Kinki/Hokuriku region, Kinki/Hokuriku

Kyusyu region, Kyusyu